Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (471-480 of 752) with videos related to

Pageof 76
Sort By:
Journal of the American College of Cardiology|February 24, 2009
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trialDan Atar, Peter Petzelbauer, Jürg Schwitter, et al.
Journal of the American College of Cardiology|March 25, 2014
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesElaine M Hylek, Claes Held, John H Alexander, et al.
Thrombosis and Haemostasis|November 22, 2014
Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?Dániel Aradi, Jean-Philippe Collet, Johannes Mair, et al.
Vascular Pharmacology|February 14, 2017
Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitroKonstantin A Krychtiuk, Christoph Kaun, Philipp J Hohensinner, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 19, 2017
PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically QuiescentPhilipp J Hohensinner, Johanna Baumgartner, Julia B Kral-Pointner, et al.
Journal of the American Heart Association|February 9, 2018
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) TrialTymon Pol, Claes Held, Johan Westerbergh, et al.
American Heart Journal|January 24, 2007
Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohortTibor Szük, Mariann Gyöngyösi, Nóra Homorodi, et al.
Critical Care Medicine|October 9, 2015
Mitochondrial DNA and Toll-Like Receptor-9 Are Associated With Mortality in Critically Ill PatientsKonstantin A Krychtiuk, Sarah Ruhittel, Philipp J Hohensinner, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 26, 2011
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on ThrombosisGregory Y H Lip, Felicita Andreotti, Laurent Fauchier, et al.
Thrombosis and Haemostasis|January 30, 2019
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-StudyMatthias K Freynhofer, Ralph Hein-Rothweiler, Paul M Haller, et al.
Pageof 76

Showing results (471-480 of 752) with videos related to

Sort By:
Pageof 76
Journal of the American College of Cardiology|February 24, 2009
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trialDan Atar, Peter Petzelbauer, Jürg Schwitter, et al.
Journal of the American College of Cardiology|March 25, 2014
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesElaine M Hylek, Claes Held, John H Alexander, et al.
Thrombosis and Haemostasis|November 22, 2014
Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?Dániel Aradi, Jean-Philippe Collet, Johannes Mair, et al.
Vascular Pharmacology|February 14, 2017
Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitroKonstantin A Krychtiuk, Christoph Kaun, Philipp J Hohensinner, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 19, 2017
PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically QuiescentPhilipp J Hohensinner, Johanna Baumgartner, Julia B Kral-Pointner, et al.
Journal of the American Heart Association|February 9, 2018
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) TrialTymon Pol, Claes Held, Johan Westerbergh, et al.
American Heart Journal|January 24, 2007
Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohortTibor Szük, Mariann Gyöngyösi, Nóra Homorodi, et al.
Critical Care Medicine|October 9, 2015
Mitochondrial DNA and Toll-Like Receptor-9 Are Associated With Mortality in Critically Ill PatientsKonstantin A Krychtiuk, Sarah Ruhittel, Philipp J Hohensinner, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 26, 2011
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on ThrombosisGregory Y H Lip, Felicita Andreotti, Laurent Fauchier, et al.
Thrombosis and Haemostasis|January 30, 2019
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-StudyMatthias K Freynhofer, Ralph Hein-Rothweiler, Paul M Haller, et al.
Pageof 76